



AT-RISK PREGNANT WOMAN WITH STICKY PLATELET SYNDROME, PREVIOUS RECURRENT PREECLAMPSIA, AND CURRENT PROTEINURIA – A RARE EXPERIENCE

Dear Editor,

We read with interest the paper written by Ruiz-Arígüelles et al.¹ in your journal describing sticky platelet syndrome (SPS) as a thrombophilic platelet function disorder^{2,3}. We report on a 35-year-old patient with SPS type II and recurrent complicated pregnancies. In 2011, she had a fetal demise in 24th week of gestation (WG); in 2012 cesarean section in 32nd WG due to preeclampsia; in 2013 premature birth in 29th WG for preeclampsia, transient loss of vision, oligohydramnion, and intrauterine growth restriction. Her father had deep venous thrombosis at the age of 50 years.

In the last pregnancy, where she carried twins, since 5th WG, besides acetylsalicylic acid (ASA) 100 mg daily, she used nadroparin 2 850 IU (anti Xa)/0.3 mL daily. Due to the allergy in the 11th WG, she switched to enoxaparin 4000 IU (40 mg)/0.4 mL daily. In the

18th WG, she complained of headaches. In the 24th WG, the patient was hospitalized due to proteinuria (0.229-0.320 g/24 h). In the 27th WG, she reported transient edema of the right leg. In the 31st WG, the patient noticed stars in the field of vision with accompanying headache. Moreover, one of the fetuses had growth restriction and reduction in placental blood flow. Therefore, an increase in the enoxaparin dose to 0.6 mL daily was recommended.

In the 33rd WG, ultrasonography normalized. After the pause in ASA (from 36th WG), enoxaparin 0.8 mL daily was recommended. In the 38th WG, she delivered healthy twins. Laboratory results are shown in Table 1; the summary of the drugs employed for the treatment, the evolution of the proteinuria and the development of the obstetric complications of the patient are outlined in Figure 1. Based on the available literature, this is the first case of a patient with combined SPS and proteinuria.


Table 1. Changes in hemostasis and further important parameters measured during pregnancy

WG	Weight (kg)	D-dimers (mg/L)	Fbg (g/L)	PLT ($\times 10^9/L$)	PS function (%)	PS antigen (%)	FVIII (IU/mL)	ProC Global NR	Anti-Xa activity (IU/mL)
11	59	0.32	3.3	264	44.2	98	2.085		0.28
18	62	0.56	3.2	223					
27	67	0.89	3	175	50.7	109		0.54	0.66
31	71	0.58	3.1	176					0.46
33	72	1.28	3.2	152				0.58	0.68
9 AD	62	0.13	2.5	268	47.4		1.294	0.63	0.62

AD: after delivery; Fbg: fibrinogen; FVIII: coagulation factor VIII; PLT: platelet count; ProC Global NR: ProC Global normalized ratio; PS: protein S; WG: week of gestation.

Reference ranges for the parameters in Table 1 according to our National Center of Hemostasis and Thrombosis: D-dimers (0.0-0.5 mg/L), Fbg (1.8-4.2 g/L), PLT (140-400 $\times 10^9/L$), PS function (60-130%), PS antigen (70-140%), FVIII (0.6-1.5 IU/mL), ProC Global NR (0.75-1.20), anti-Xa activity for the prophylactic dose of LMWH (0.2-0.4 IU/mL), for the therapeutic dose of LMWH (0.5-1.2 IU/mL).

Figure 1. Timeline of the development of patient's complications during at-risk pregnancy.



ASA: acetylsalicylic acid; PAMBA: para-aminobenzoic acid; WG: week of gestation.

ACKNOWLEDGMENTS

The study was supported by the projects of the Scientific Grant Agency (Vega) Vega 1/0168/16, 1/0549/19 and Vega 1/0479/21, and the Agency for the Support of Research and Development (APVV) APVV-16-0020 received by our faculty.

The case was managed according to the Declaration of Helsinki and approved on December 11, 2013 by the Ethics Committee of the Jessenius Faculty of Medicine in Martin (Project identification code EK 1422/2013). The patient gave her informed consent for inclusion.

REFERENCES

1. Ruiz-Argüelles GJ, Ruiz-Delgado GJ, López-Martínez B. The sticky platelet syndrome: a frequent but unrecognized cause of thrombophilia. *Rev Invest Clin.* 2002;54:394-6.
2. Kubisz P, Stasko J, Holly P. Sticky platelet syndrome. *Semin Thromb Hemost.* 2013;39:674-83.
3. Kubisz P, Ruiz-Argüelles GJ, Stasko J, Holly P, Ruiz-Delgado GJ. Sticky platelet syndrome: history and future perspectives. *Semin Thromb Hemost.* 2014;40:526-34.

LUCIA STANČIAKOVÁ¹, MIROSLAVA DOBROTOVÁ¹, JELA IVANKOVÁ¹, INGRID ŠKORNÍKOVÁ¹, TOMÁŠ BOLEK², MONIKA BRUNCLÍKOVÁ¹, MATEJ SAMOŠ², JÁN DANKO³, MÁRIA ŠKEREŇOVÁ⁴, PETER KUBISZ¹, AND JÁN STAŠKO¹

Departments of ¹Hematology and Transfusion Medicine, National Center of Hemostasis and Thrombosis, ²Internal Medicine, ³Gynecology and Obstetrics, and ⁴Biomedical Center, Martin University Hospital, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic

*Corresponding author:

Lucia Stančiaková

E-mail: stanciakova2@unioba.sk

Received for publication: 19-12-2022

Approved for publication: 12-01-2023

DOI: 10.24875/RIC.22000307